K8凯发
中
Home
About TUL
Group Introduction
Executive Directors
Subsidiaries
Contact Us
Innovation in R&D
R&D Pipeline
R&D Platform
R&D Updates
News
TUL Highlights
Product Center
Finished Products
Comprehensive Health Products
APIs and Intermediates
Animal protection products
Empty capsule
Medical device
Cosmetic Peptide Products
Sustainability
Enhancing Governance
Normalizing Healthiness
Brand Building
People-Oriented
Green Development
ESG Reports
ESG News
K8凯发:R&D Platform
K8凯发:R&D Updates
All News
Select Year
2025
2024
The Marketing Application of TUL’s Semaglutide Injection Accepted by the National Medical Products Administration
2025-01-24
Prev
1
2
Next
Scan the Code to Follow Us
WeChat Official Account
WeChat Channel
About TUL
K8凯发:Innovation in R&D
News
K8凯发:Product Center
K8凯发:Sustainability
Copyright © 2025 TUL. All Rights Reserved.
粤ICP备17098416号-3
K8凯发:Legal Notice
K8凯发:Privacy Statement
WeChat
Officialt
Account
To Top